AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab ...
Positive results from the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane …